Last Price$1.3(9.4%)
Market Cap$8,155.2K
LTM FCF to Net Income
85.9%
5Y avg
62.3%
Medical - Instruments & Supplies industry
median
73.6%
Stock quality & Intrinsic value
4/10
3.0% undervalued
Predictive Oncology Inc. FCF to Net Income
Annual
Quarterly
LTM
Industry median
Company stand-alone
Crunching data... Almost there!
| Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FCF to Net Income | 53.5% | 45.3% | 60.7% | 39.7% | 16.0% | 43.3% | 51.1% | 157.6% | 67.8% | 58.3% | 54.7% | 45.2% | 48.7% | 67.0% | 49.9% | 96.5% |
Overvalued or undervalued?
Check the intrinsic value for POAI
and see if it's the right time to invest.
Predictive Oncology Inc. (POAI) FCF to Net Income comparison analysis
General
LTM FCF to Net Income
OTHER METRICS
Company name
Revenue growth
EPS growth
Net Income margin
Predictive Oncology Inc.POAI
85.9%
18.2%
(64.9%)
(785.6%)
Median Peer Set
83.4%
3.4%
23.0%
10.4%
Becton, Dickinson and CompanyBDX
170.0%
4.2%
18.3%
8.4%
Hologic, Inc.HOLX
152.6%
(0.0%)
81.1%
19.6%
Alcon Inc.ALC
129.1%
8.5%
182.9%
10.3%
ResMed Inc.RMD
111.2%
10.9%
13.4%
21.8%
AptarGroup, Inc.ATR
93.3%
2.7%
30.2%
10.5%
The Cooper Companies, Inc.COO
73.4%
8.4%
32.2%
10.1%
West Pharmaceutical Services, Inc.WST
56.1%
(1.9%)
(15.5%)
17.0%
Intuitive Surgical, Inc.ISRG
46.2%
17.2%
27.7%
27.8%
Masimo CorporationMASI
(47.7%)
0.6%
(42.5%)
4.0%
Baxter International Inc.BAX
(91.9%)
(69.5%)
(100.0%)
(6.9%)
POAI key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 0.0 0.0% | 0.0 0.0% | 0.0 (98.2%) | 0.1 33,454.5% | 0.2 95.3% | 0.5 148.0% | 1.0 103.3% | 0.7 (31.2%) | 0.5 (30.2%) | 0.7 43.4% | 1.4 115.6% | 1.4 (0.0%) | 1.3 (11.3%) | 1.4 13.4% | 1.5 6.0% | 1.8 18.2% |
| Cost of Goods Sold (COGS) | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.2 | 0.4 | 0.3 | 0.2 | 0.1 | 0.4 | 0.5 | 0.4 | 0.5 | 0.5 | 0.6 |
% margin | 0.0 0.0% | 0.0 55.5% | 0.0 51.4% | 0.0 42.0% | 0.1 31.9% | 0.3 59.5% | 0.6 59.5% | 0.4 53.5% | 0.3 60.2% | 0.5 77.4% | 1.0 70.5% | 0.9 62.3% | 0.8 64.3% | 0.9 65.7% | 1.0 66.4% | 1.1 64.3% |
| Operating Expenses | 1.7 | 2.5 | 1.2 | 4.1 | 7.2 | 9.2 | 7.0 | 4.8 | 6.8 | 8.3 | 8.9 | 14.7 | 13.3 | 14.4 | 16.3 | 15.1 |
| Research & Development Expenses (R&D) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.2 | 0.4 | 0.3 | 0.4 | 0.3 | 1.9 | 3.0 | 2.4 | 0.3 | 0.3 | 0.2 |
| Selling, General & Administrative Expenses (SG&A) | 1.4 | 2.0 | 2.1 | 4.1 | 7.2 | 9.2 | 7.0 | 4.8 | 5.6 | 8.3 | 7.0 | 11.7 | 10.9 | 11.7 | 12.5 | 10.9 |
% margin | (1.7) 0.0% | (2.4) (15,528.1%) | (1.2) (418,616.7%) | (4.1) (4,248.3%) | (7.2) (3,792.8%) | (8.9) (1,907.1%) | (6.5) (679.7%) | (4.4) (672.4%) | (6.5) (1,429.6%) | (7.7) (1,183.0%) | (7.9) (556.9%) | (13.8) (975.8%) | (0.7) (53.2%) | (13.5) (948.2%) | (15.3) (1,014.2%) | (13.9) (782.1%) |
| Interest Income | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Interest Expense | 0.1 | 0.1 | 0.1 | 0.2 | 0.3 | 0.6 | 0.4 | 0.4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 10.7 | 0.0 |
| Pre-tax Income | 0.0 | (1.8) | (1.4) | (4.5) | (7.4) | (9.4) | (6.8) | (4.8) | (6.5) | (7.7) | (10.1) | (19.4) | (25.9) | (20.3) | (25.7) | (14.0) |
% effective tax rate | 0.1 0.0% | 0.4 (25.4%) | 0.0 0.0% | 0.2 (5.1%) | 0.3 (3.5%) | 0.6 (6.8%) | 0.4 (5.5%) | 0.0 0.0% | 0.0 0.0% | 0.1 (0.7%) | (2.2) 22.1% | 8.2 (42.1%) | 11.8 (45.7%) | (0.7) 3.3% | 10.5 (40.7%) | 0.0 0.0% |
% margin | (1.8) 0.0% | (2.9) (18,378.5%) | (1.4) (469,690.6%) | (4.5) (4,643.0%) | (7.4) (3,931.8%) | (9.4) (2,009.4%) | (6.8) (718.1%) | (4.8) (732.1%) | (6.5) (1,429.6%) | (7.7) (1,183.0%) | (10.1) (714.5%) | (27.6) (1,952.2%) | (37.7) (3,010.7%) | (19.7) (1,383.6%) | (36.2) (2,405.1%) | (14.0) (785.6%) |
| EPS | (65,282.52) | (96,407.67) | (36,559.70) | (52,786.81) | (26,794.78) | (16,051.71) | (11,057.55) | (4,601.85) | (462.31) | (243.50) | (157.40) | (192.02) | (63.10) | (7.16) | (9.92) | (3.48) |
| Diluted EPS | (65,282.52) | (96,407.67) | (36,559.70) | (52,786.81) | (26,794.78) | (16,051.71) | (11,057.55) | (4,601.85) | (462.31) | (243.50) | (157.40) | (192.02) | (63.10) | (7.16) | (9.92) | (3.48) |
% margin | (1.7) 0.0% | (2.8) (17,857.6%) | (1.2) (417,773.3%) | (4.3) (4,401.3%) | (7.2) (3,793.9%) | (8.8) (1,871.6%) | (6.4) (671.8%) | (4.3) (660.4%) | (6.4) (1,411.5%) | (6.0) (913.5%) | (7.7) (546.4%) | (12.4) (879.4%) | (11.5) (915.0%) | (12.1) (853.9%) | (14.0) (926.9%) | (13.2) (740.5%) |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is Predictive Oncology Inc.'s FCF to Net Income?
As of today, Microsoft Corp's last 12-month FCF to Net Income is 85.9%, based on the financial report for Sep 30, 2024 (Q3’2024). The average annual FCF to Net Income for Predictive Oncology Inc. have been 66.6% over the past three years, and 65.4% over the past five years.
2) Is Predictive Oncology Inc.'s FCF to Net Income Good?
As of today, Predictive Oncology Inc.'s FCF to Net Income is 85.9%, which is higher than industry median of 73.6%. It indicates that Predictive Oncology Inc.'s FCF to Net Income is Good.